Identifying genetic markers for better treatment of B-cell lymphoma
Official title: Genetic and Epigenetic Biomarkers for B-cell Lymphoma
Funded at Duke University · NIH-10674524 · Data updated 2026-11-12
This study is looking at how certain genes might help doctors understand how well patients with diffuse large B-cell lymphoma (DLBCL) will respond to common treatments, so they can improve care and outcomes for everyone affected by this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | January 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $360,922 |
| NIH project number | 5R01CA233490-06 |
| Project ID | NIH-10674524 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with diffuse large B-cell lymphoma who are undergoing or have completed treatment.
✕Less likely to help
Patients with other types of lymphoma or those who do not have a diagnosis of diffuse large B-cell lymphoma may not benefit from this research.
What this research studies
This research focuses on diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma in the U.S. The study aims to identify genetic and epigenetic biomarkers that can help predict how patients will respond to standard treatments like R-CHOP. By analyzing the TP53 gene and its role in tumor behavior, researchers hope to improve prognosis and treatment strategies for patients with DLBCL. The approach involves collaboration with multiple medical centers to gather comprehensive data on patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with B-cell lymphoma, improving survival rates.
How similar studies have gone: Previous research has shown promise in using genetic markers to predict treatment outcomes in various cancers, suggesting that this approach could be effective for DLBCL as well.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Young, Ken H. — Duke University
- Study coordinator: Young, Ken H.
Related research
Other NIH-funded projects on the same topics.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
Spatially resolved single-cell biomarkers to guide B cell lymphoma therapy
Aims to map tiny details in the tumor and immune cells of diffuse large B-cell lymphoma to help predict outcomes and guide treatments.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.